Hereditary Hemochromatosis

Hereditary hemochromatosis (HH) is a genetic disorder of iron metabolism characterized by progressive iron overload and end-organ damage, most commonly due to mutations in the HFE gene ^[1]B2a[3]D5. Also called HFE hemochromatosis, classic hemochromatosis, or historically bronze diabetes, HH encompasses a spectrum of inherited iron-loading diseases that share a common final pathway: dysregulation of hepcidin, the master regulator of iron homeostasis ^[3]D5[4]D5.

Classification of Hereditary Hemochromatosis

HH is classified by the underlying genetic defect, which determines the age of onset, severity, and mode of inheritance. The WHO/ICC classification recognizes four main types based on the affected gene and the functional consequence, hepcidin deficiency (types 1, 2, 3) versus hepcidin resistance (type 4) ^[3]D5[4]D5.

Type 1 (HFE) accounts for over 90% of symptomatic HH in populations of European descent ^[1]B2a[4]D5. Homozygosity for the p.Cys282Tyr (p.C282Y) variant is the predominant genotype, with a prevalence of approximately 1 in 200 in Northern European cohorts ^[1]B2a[6]C4. The penetrance of clinical disease is incomplete: up to 38% to 50% of C282Y homozygotes develop biochemical iron overload, but only 10% to 33% progress to hemochromatosis-associated morbidity ^[1]B2a. This variability is influenced by genetic modifiers, sex, and environmental factors ^[2]B2b[4]D5.

Non-HFE forms (types 2-4) are rarer but should be suspected when iron overload presents at a young age (type 2), in the absence of HFE mutations, or with a dominant inheritance pattern (type 4) ^[3]D5. Accurate classification is essential for genetic counseling, surveillance, and management , as disease severity and treatment response differ by type ^[4]D5.

Pearl: In clinical practice, any patient with unexplained elevated transferrin saturation and ferritin should undergo HFE genotyping for p.C282Y and p.H63D; a negative result in a high-suspicion case warrants consideration of non-HFE types and referral for specialized iron studies ^[5]C4.

Building on the classification of HFE and non-HFE subtypes, the core pathogenic defect in all forms of hereditary hemochromatosis (HH) is a relative deficiency of the iron-regulatory hormone hepcidin. Hepcidin, produced by hepatocytes, controls systemic iron homeostasis by binding to the iron exporter ferroportin (FPN1) on enterocytes and macrophages, triggering its internalization and degradation. In HH, hepcidin deficiency leaves FPN1 stabilized on cell surfaces, leading to unbridled dietary iron absorption from the duodenum and unrestrained iron release from reticuloendothelial macrophages. This dual dysregulation drives progressive iron loading in parenchymal organs, particularly the liver, heart, pancreas, and skin, while paradoxically sparing macrophages, a pattern that distinguishes HH from secondary iron overload ^[19]D5.

The HFE-BMP/SMAD Signaling Axis

The most common form of HH, type 1, results from mutations in the HFE gene, most often the p.C282Y substitution. HFE facilitates signaling through the bone morphogenetic protein (BMP) pathway, which is the dominant transcriptional activator of the hepcidin gene HAMP. HFE physically interacts with the BMP type I receptor ALK3 (BMPR1A); this interaction inhibits ALK3 ubiquitination and proteasomal degradation, increasing ALK3 protein expression at the hepatocyte cell surface ^[12]D5. In Hfe-deficient mice, hepatic ALK3 protein levels decline, and despite elevated Bmp6 mRNA and protein, downstream phosphorylation of Smad1/5/8 and target gene expression (e.g., Id1) remain inappropriately low ^[11]D5. The result is a failure of iron to induce hepcidin transcription. Liver-specific deletion of Alk3 in mice produces a nearly complete loss of basal BMP signaling and hepcidin expression, causing severe iron overload ^[13]D5. HFE mutants C282Y and H63D both fail to increase ALK3 cell-surface expression ^[12]D5. Moreover, HFE requires the co-receptor hemojuvelin (HJV) to stimulate hepcidin; transgenic overexpression of Hfe cannot induce hepcidin in Hjv-deficient mice ^[15]D5.

Angiocrine and Alternative Pathways

Hepatic sinusoidal endothelial cells (LSECs) supply an additional BMP ligand, BMP2, that drives hepcidin expression independently of BMP6. Conditional deletion of Bmp2 in LSECs using Stab2-Cre mice causes massive hepatic iron overload, reduced hepcidin, and a phenotype resembling classic HH ^[9]D5. Combined loss of endothelial Bmp2 and Hjv produces more severe hepcidin deficiency and iron loading than either alone, and iron fails to induce hepcidin at all in Bmp2/Hjv double knockouts ^[32]D5. Conversely, BMP5 loss does not worsen the phenotype of Hfe-/- mice, indicating pathway specificity ^[32]D5.

Genetic Modifiers of Hepcidin Expression and Penetrance

Penetrance of HH is highly variable. Only 28.4% of male and 1.2% of female C282Y homozygotes develop iron-overload-related disease ^[16]B2b. This variability arises from both genetic and environmental modifiers.

• CYBRD1: A promoter polymorphism (rs884409) in CYBRD1 (encoding duodenal cytochrome b reductase) is associated with lower serum ferritin in C282Y homozygotes. Median ferritin in male C282Y homozygotes fell from 1194 μg/L (no copy) to 387 μg/L (one copy). The rare allele reduces promoter activity by 30% ^[7]B2b. A linked variant, rs3806562, associates with transferrin saturation ^[21]C4.
• TMPRSS6: This transmembrane serine protease inhibits hepcidin by dampening BMP/SMAD signaling. Heterozygous loss of Tmprss6 in Hfe-/- mice reduces systemic iron overload; homozygous loss causes iron deficiency with elevated hepcidin, demonstrating that TMPRSS6 inhibition can upregulate hepcidin in an HFE-independent manner ^[10]D5. Natural variation in TMPRSS6 may modify clinical penetrance in humans.
• Environmental cofactors: Excess alcohol consumption is a major cofactor accelerating fibrosis; steatosis and viral hepatitis also contribute ^[8]D5.

Non-HFE Forms of Hereditary Hemochromatosis

Type 2 (juvenile HH) involves mutations in HJV (hemojuvelin) or HAMP itself, leading to severe, early-onset hepcidin deficiency ^[27]C4. Type 3 (mutations in TFR2) disrupts an alternative iron-sensing pathway; a novel homozygous TFR2 p.G446E mutation in a Japanese patient produced transferrin saturation of 92.2% and serum ferritin of 1611.8 ng/mL with a hepcidin-25 level of only 2.9 ng/mL ^[28]C4. Type 4 (ferroportin disease) is an autosomal dominant disorder caused by loss-of-function FPN1 mutations; unlike HH, it features iron trapping in macrophages, low transferrin saturation, and a tendency to anemia ^[18]D5.

Iron-Driven Tissue Injury

Unbound iron catalyzes Fenton chemistry, generating reactive oxygen species that damage cellular membranes, proteins, and DNA. In the liver, this triggers stellate cell activation, fibrogenesis, and eventually cirrhosis. The risk of hepatic fibrosis correlates with the degree of iron loading, with threshold hepatic iron concentrations identified from population studies ^[8]D5. Hepatic iron accumulation also drives hepatocellular carcinoma through oxidative stress and genomic instability. In the heart, iron deposition causes cardiomyopathy; in the pancreas, beta-cell dysfunction leads to diabetes; in the skin, iron deposition in sun-exposed areas produces a bronze hyperpigmentation ^[25]B2a.

Pearl: The therapeutic principle of phlebotomy, removing iron-laden red cells, directly counteracts the hepcidin-deficient state by depleting body iron stores, but it does not correct the underlying hepcidin deficit; emerging therapies aim to restore hepcidin signaling via BMP agonists or TMPRSS6 inhibition ^[10]D5[20]D5.

Building on the genetic basis of hepcidin dysregulation, the epidemiological profile of hereditary hemochromatosis reveals a disease with high prevalence of the at-risk genotype but low penetrance, driven by both inherited and modifiable factors. The HFE C282Y homozygous state occurs in approximately 1 in 200-300 individuals of Northern European ancestry, yet only about 20% of homozygotes develop clinical iron overload ^[37]B2b. In Finland, hemochromatosis may be under-recognized, and large-scale data from the FinnGen cohort (420 543 individuals) have refined risk quantification ^[37]B2b.

Men are affected earlier and more severely than women, with clinical disease typically emerging after age 40 in men and after menopause in women. Among East Asian HJV-HH cases, males are more often affected than females, whereas in Caucasians the sexes are equally represented among biallelic cases ^[33]C4. The most common genotype worldwide is HFE C282Y/C282Y, but rare mutations in HJV (e.g., G320V in Caucasians, Q6H/C321* in Chinese) also cause early-onset HH ^[33]C4.

Risk Modifiers for Clinical Hemochromatosis

Blood donation at least twice a year is sufficient to lower the risk of clinically significant hemochromatosis in C282Y homozygotes from a male risk of 0.16 to approximately 0.018, equivalent to that of compound heterozygotes ^[37]B2b. The S65C variant confers protection against severe disease, while the CASC15 variant (rs181949568) increases odds sevenfold ^[37]B2b.

Clinical Consequences of Risk

Patients with HH have a significantly increased need for joint replacement surgery: pooled RR 3.32 for any joint, with hip replacement RR 2.62 and ankle replacement RR 8.94 ^[35]B2a. Hepatocellular carcinoma in HH occurs predominantly in men (97% male in a matched cohort), but survival after curative therapy is comparable to that of other liver disease etiologies (5‑year survival 77%) ^[36]B2b. A meta-analysis found a trend toward increased breast cancer risk in C282Y homozygotes (OR 1.36), but heterogeneity was high and the finding does not yet support altered screening ^[34]B2a.

Pearl: The penetrance of C282Y homozygosity is only 20%; blood donation twice a year can reduce the risk of clinical hemochromatosis from that of a high-risk homozygote to that of a low-risk compound heterozygote ^[37]B2b.

The transition from population genetics to bedside begins with the recognition that hereditary hemochromatosis (HH) often presents indolently, with symptoms that are easily dismissed as age-related or idiopathic. The classic triad of bronze skin, diabetes, and cirrhosis is now rarely seen at initial diagnosis because earlier detection through iron studies has shifted the clinical spectrum toward milder, nonspecific complaints ^[41]C4.

Presenting Symptoms

Dermatologic Manifestations

Skin hyperpigmentation, a bronze or slate-gray hue, is the hallmark cutaneous finding, most prominent on sun-exposed areas (face, dorsum of hands, forearms) ^[25]B2a. Hypertrichosis (excessive hair growth) and resistant pruritus are also described ^[25]B2a. Importantly, porphyria cutanea tarda (PCT) co-occurs with HH in a subset of patients, and HH should be considered in any patient with PCT ^[25]B2a. There is controversial evidence suggesting an association between HH and skin cancers, though the causal link remains unclear ^[25]B2a.

Examination Findings

In addition to skin changes, the clinician should look for hepatomegaly, cirrhosis|stigmata of chronic liver disease (spider angiomas, palmar erythema, caput medusae), and signs of heart failure (elevated jugular venous pressure, peripheral edema). Testicular atrophy may be present in men due to iron deposition in the pituitary or gonads ^[27]C4. Neurological examination is typically normal in uncomplicated HH, but peripheral neuropathy may develop secondary to diabetes, and signs of hepatic encephalopathy (asterixis, altered mental status) can emerge with advanced cirrhosis.

Phenotypic Variants

Red Flags

• Progressive fatigue and arthralgias in a middle-aged man should prompt ferritin and TSAT measurement.
• Unexplained cirrhosis, diabetes, or cardiomyopathy, especially when multiple are present, warrants iron studies.
• Susceptibility to Yersinia infections: HH impairs neutrophil function, increasing risk of severe yersiniosis , which can present with fever, abdominal pain, and sepsis ^[29]D5.

Atypical Presentations

A substantial proportion of patients are asymptomatic, with iron overload discovered incidentally on routine labs ^[41]C4. Others may present with isolated hypogonadism or arthropathy years before liver disease appears. The absence of the classic triad does not rule out HH; the disease should be considered in any patient with unexplained elevated transferrin saturation or ferritin, especially with a family history ^[41]C4.

Pearl: The classic triad of bronze skin, diabetes, and cirrhosis is now a late-stage finding. In contemporary practice, suspect HH in any patient with unexplained fatigue, bilateral metacarpophalangeal joint pain, and elevated transferrin saturation, particularly if accompanied by a family history of liver disease or arthritis.

The clinical suspicion raised by unexplained hepatic iron overload, with or without extrahepatic manifestations, must be confirmed through a systematic diagnostic workup anchored in iron studies and genetic testing. The hematology laboratory provides the key confirmatory tests, with molecular profiling serving as the gold standard for definitive subtyping.

Peripheral Blood Smear

The peripheral blood smear is typically unremarkable in early hereditary hemochromatosis (HH). With progressive liver disease, findings may include macrocytosis (mean corpuscular volume often >100 fL), thrombocytopenia (platelet count <150 × 10⁹/L due to hypersplenism), and poikilocytosis (target cells, acanthocytes). In advanced cirrhosis, leukoerythroblastosis (nucleated RBCs, immature granulocytes) may appear. Anemia is not a feature of uncomplicated HH; when present, it suggests a coexisting disorder such as iron deficiency due to chronic blood loss or anemia of chronic disease ^[44]C4. The blood film is essential for ruling out other causes of microcytic anemia (e.g., iron deficiency, thalassemia) that may confound ferritin interpretation.

Bone Marrow Examination

Bone marrow aspiration and biopsy are not routinely indicated for HH diagnosis. However, they are valuable when the presentation is atypical, for example, unexplained cytopenias, suspected myelodysplastic syndrome, or when iron studies are discordant (e.g., elevated ferritin with normal transferrin saturation). When performed, Prussian blue (Perls) stain reveals markedly increased iron stores in both macrophages (grade 3-4+ in the Gale scale) and erythroid precursors. The presence of ringed sideroblasts is not a feature of HH; their detection should prompt evaluation for myelodysplasia or sideroblastic anemia. In ferroportin disease (autosomal dominant), marrow examination shows selective iron trapping in macrophages with relatively spared erythroid iron content, reflecting the loss-of-function defect in iron export ^[18]D5.

Flow Cytometry

Flow cytometry plays no primary role in HH diagnosis. It is reserved for excluding hematologic malignancies or immune-mediated cytopenias when the clinical picture is complicated by unexplained lymphadenopathy, splenomegaly, or abnormal blood counts. No specific HH-associated immunophenotypic aberrancy has been described.

Molecular Genetic Profiling

Molecular testing is the cornerstone of definitive diagnosis and subtyping. The gold standard is identification of a pathogenic mutation in an iron-regulating gene. The approach is stepwise:

1. First-line HFE genotyping for the common p.Cys282Tyr (C282Y) and p.His63Asp (H63D) variants. The p.Ser65Cys (S65C) variant is included in some panels ^[37]B2b. C282Y homozygosity accounts for 80-90% of clinically expressed HH in populations of Northern European descent. Compound heterozygosity (C282Y/H63D) confers a lower penetrance ^[37]B2b.

2. Non-HFE gene sequencing (HJV, HAMP, TFR2, SLC40A1) is indicated when HFE testing is negative but iron overload is confirmed, especially in patients of non-European ancestry, juvenile onset (age <30 years), or severe phenotype (cardiomyopathy, hypogonadism) ^[42]C4. HJV and HAMP mutations cause the most severe forms (type 2A/2B), with earlier age of onset and higher prevalence of cardiac and endocrine involvement compared to HFE-HH ^[42]C4. TFR2 mutations (type 3) produce an intermediate severity ^[28]C4[42]C4. SLC40A1 mutations cause ferroportin disease (type 4), characterized by hyperferritinemia with normal or low transferrin saturation ^[18]D5.

3. Clinical exome sequencing (CES) is emerging for unexplained hyperferritinemia after exclusion of HFE p.Cys282Tyr homozygosity. In a cohort of 108 patients, CES identified at least one variant in 66.7%, with 40.7% harboring a likely pathogenic/pathogenic variant. Digenic or oligogenic inheritance was observed in 30.6% of patients, most frequently involving HFE-SERPINA1 and HFE-ATP7B combinations ^[46]C4. These findings support a broader genetic landscape beyond the traditional Mendelian framework.

4. Hepcidin-25 measurement (low in hepcidin-deficient forms, normal or elevated in ferroportin disease) is available in specialized centers but not yet standardized for routine clinical use ^[28]C4.

Diagnostic Algorithm in Practice

For the clinician, a practical algorithm is: (1) Screen with transferrin saturation (TSAT) and serum ferritin. TSAT >45% is the most sensitive initial test; TSAT >60% in men or >50% in women with elevated ferritin (≥300 µg/L in men, ≥200 µg/L in women) warrants genetic testing ^[45]A1c. (2) Obtain HFE genotyping. (3) If negative and iron overload is confirmed (by MRI R2* or liver biopsy with quantitative iron >80 µmol/g dry weight), proceed to non-HFE gene panel or CES. (4) In ambiguous cases, bone marrow biopsy may help differentiate ferroportin disease from other causes.

Pearl: Transferrin saturation is the single most useful screening test; a normal TSAT (<45%) effectively excludes classic hepcidin-deficient HH, even in the presence of hyperferritinemia. In such cases, consider ferroportin disease, alcoholic liver disease, or metabolic syndrome.

Controversies and Guideline Disagreement

Section 6 will detail how the diagnostic findings are integrated into risk stratification and prognostic scoring.

With the diagnosis confirmed by iron studies and HFE genotyping, the next step is to quantify the burden of iron overload and assess for end-organ damage, this stratification maps directly to treatment intensity and predicts long-term outcomes.

Quantifying Iron Overload

Liver iron concentration (LIC) is the gold standard for staging iron overload severity. Noninvasive MRI relaxometry (R2 and R2* techniques) provides accurate LIC estimates without the risks of biopsy ^[52]D5[53]D5. Dual-energy CT and emerging sequences (UTE, QSM, Dixon) further expand imaging options, though international standardization of protocols is still needed ^[53]D5. Histologic assessment using the Deugnier and Turlin semiquantitative score remains available when biopsy is performed. The digital hepatic iron index (HII), derived from AI-based analysis of Prussian blue-stained slides, shows excellent discrimination for HFE-related iron overload: an HII > 1.9 yields an AUC of 0.94 for identifying patients with homozygous or heterozygous HFE mutations ^[54]C4.

Risk Stratification for Liver Fibrosis

Patients with hereditary hemochromatosis who maintain serum ferritin > 1000 μg/L or LIC > 7 mg/g dry weight are at highest risk for bridging fibrosis and cirrhosis ^[30]D5. The presence of cirrhosis shifts prognosis dramatically: it increases the risk of hepatocellular carcinoma (HCC) and mandates surveillance. The Barcelona Clinic Liver Cancer ( BCLC ) staging system accurately stratifies survival in HH patients who develop HCC, and HH as an etiology does not independently worsen outcomes compared with other liver diseases (HR 0.949; P = 0.839) ^[36]B2b.

Prognostic Factors Table

Transferrin saturation > 60% is a reliable indicator of circulating non-transferrin-bound iron, the labile form directly linked to tissue toxicity ^[48]C4.

Long-Term Sequelae and Recovery Timeline

With aggressive phlebotomy, iron stores can be normalized within 12-24 months in most patients. However, established cirrhosis, arthropathy, and diabetes are generally irreversible. In HH patients who develop HCC, 5-year survival after curative therapy ( liver transplantation , resection, or radiofrequency ablation ) is 77%, compared with only 15% after noncurative locoregional treatment ^[36]B2b. The presence of ischemic heart disease independently reduces survival (multivariate HR not reported) ^[36]B2b.

Controversies

Pearl: The single most actionable prognostic threshold is hepatic iron index > 1.9 (AUC 0.94) and serum ferritin > 1000 μg/L, both mandate aggressive phlebotomy and close surveillance for cirrhosis and HCC.

Following risk stratification, the clinician must recognize two acute emergencies that can arise in hereditary hemochromatosis: acute decompensated heart failure (ADHF) due to cardiac iron overload and severe systemic infections, particularly with siderophilic organisms. These events require immediate, coordinated intervention.

Step 1: Initial Assessment and Severity Classification

When a patient with known or suspected hereditary hemochromatosis presents with dyspnea, hypotension, or shock, the first priority is to differentiate between cardiac and septic etiologies, which may coexist. Cardiac T2 MRI <10 ms* is the most important predictor of heart failure from cardiac iron overload ^[56]D5 (5). If the patient is unstable, obtain an urgent echocardiogram and measure serum ferritin, transferrin saturation, and a complete blood count with differential. Sepsis must be suspected in any febrile patient with HH, especially if they have recently consumed raw shellfish or have a history of liver disease. The Mottelson cohort study (N=142,188) found that C282Y homozygotes have a hazard ratio for any infection of **1.40 ** and for sepsis of **1.69 ** ^[55]B2b (2b). Even C282Y homozygotes with normal iron indices have increased infection risk ^[55]B2b.

Step 2: First-Line Intervention - Acute Heart Failure

In patients with ADHF secondary to cardiac iron overload, the first principle is urgent continuous intravenous deferoxamine to control free iron toxicity. The AHA consensus statement recommends initiating a continuous intravenous infusion of deferoxamine at 40-50 mg/kg over 24 hours (without interruption) ^[56]D5 (5). This is a medical emergency and requires consultation with a center experienced in iron overload management . Do not use diuretics or inotropes aggressively because the chronic anemia adaptation in HH (resting tachycardia, high cardiac output, enlarged end-diastolic volume) makes these patients sensitive to volume shifts ^[56]D5. The goal of chelation is to reduce myocardial iron rapidly; oral deferiprone may be added as augmentation therapy (see Dosing Table).

Step 3: First-Line Intervention - Sepsis

For suspected sepsis, immediately obtain blood cultures and start empiric broad-spectrum antibiotics that cover both gram-negative enteric organisms and siderophilic pathogens such as Yersinia enterocolitica and Vibrio vulnificus. A reasonable empiric regimen is ceftriaxone 2 g IV daily plus doxycycline 100 mg IV twice daily (or a fluoroquinolone if allergic). The mouse model by Das et al. suggests that type I interferon signaling impairs neutrophil function in HH, leading to expansion of immature CD101⁻ neutrophils ^[29]D5 (5); this mechanistic insight supports the need for aggressive early antimicrobial therapy. Chelation may need to be temporarily withheld during acute sepsis because iron chelators can interfere with the host immune response, but this decision should be individualized with expert consultation.

Step 4: Monitoring and Titration

During ADHF treatment, monitor daily: (1) cardiac T2* MRI (if feasible) or echocardiographic LVEF; (2) serum ferritin and transferrin saturation; (3) renal function and electrolytes. The deferoxamine infusion should be continued uninterrupted until the patient is hemodynamically stable and cardiac T2* improves to >10 ms. For sepsis, monitor blood cultures, white blood cell count, and procalcitonin. If the patient does not improve within 48 hours, consider desferrioxamine-induced Yersinia sepsis (a known phenomenon) and switch to a chelator with lower siderophore activity, such as deferasirox, under expert guidance.

Step 5: Resolution and Transition

Once the acute episode resolves, transition to a long-term oral chelation regimen (see Section 8: Long-term & Definitive Management). The patient should be counseled on the lifelong increased risk of infections, especially from Yersinia and Vibrio, and advised to avoid raw shellfish and undercooked meat.

Treatment Algorithm

Figure 1: Acute management pathway for HH emergencies (adapted from ^[56]D5).

Dosing Table

What NOT to Do

• Do not administer diuretics or inotropes aggressively in ADHF due to cardiac iron overload; the high-output state of chronic anemia makes these patients susceptible to hypotension and arrhythmias ^[56]D5.
• Do not withhold antibiotics while awaiting culture results in a febrile HH patient; the hazard ratio for sepsis is 1.69 even in the absence of overt iron overload ^[55]B2b.
• Do not use deferoxamine alone for sepsis if the patient is already on it; there is a risk of promoting Yersinia growth. Switch to deferasirox if possible.

Controversies and Guideline Disagreement

Pearl: In any HH patient with acute decompensation, measure cardiac T2* emergently; if <10 ms, start continuous IV deferoxamine 40-50 mg/kg/24h and do not use aggressive diuretics ^[56]D5. If fever is present, treat empirically for Yersinia/Vibrio with ceftriaxone plus doxycycline, noting that the infection risk is elevated even in those with normal iron indices ^[55]B2b.

Once acute iron overload has been addressed and the diagnosis confirmed, the goal shifts to sustained iron depletion and prevention of organ damage. The management of hereditary hemochromatosis (HH) rests on a foundation of therapeutic phlebotomy, with iron chelation reserved for a minority of patients and lifestyle modification serving as an essential adjunct. The following stepwise protocol reflects the evidence-based approach endorsed by the Chinese Society of Hepatology (2024) and the ASH Education Program (2024) ^{[45]A1c[68]D5}.

Step 1: Induction Phlebotomy, Iron Depletion

Initiate weekly or biweekly phlebotomy of 500 mL whole blood (equivalent to approximately 200-250 mg of iron). The goal is to reduce serum ferritin to <50 ng/mL while maintaining a hemoglobin level ≥11 g/dL ^{[45]A1c[68]D5}. Transferrin saturation is a secondary target; it typically falls below 50% once iron stores are depleted but may remain elevated in some patients. The frequency of phlebotomy is adjusted based on baseline ferritin and tolerance. In elderly patients or those with comorbid anemia, a more gradual schedule (e.g., 250-400 mL every 2 weeks) is appropriate. Induction typically requires 20-40 sessions over 6-12 months, depending on the initial iron burden. Monitor hemoglobin before each phlebotomy; defer if hemoglobin <11 g/dL or if the patient develops symptoms of anemia ^[68]D5.

Step 2: Maintenance Phlebotomy, Sustaining Iron Balance

After iron depletion is achieved, a maintenance regimen is required to prevent reaccumulation. Perform phlebotomy every 3-4 months to keep serum ferritin between 50 and 100 ng/mL ^[68]D5. In many patients, maintenance phlebotomy can be transformed into a regular blood donation program, provided the donated blood is acceptable for transfusion. A large FinnGen cohort study demonstrated that asymptomatic C282Y homozygotes who donate blood at least twice a year reduce their risk of developing clinically significant hemochromatosis to levels comparable to compound heterozygotes ^[37]B2b. This approach is both cost-effective and socially beneficial. Erythrocytapheresis, which selectively removes red cells while returning plasma, is an alternative that may be more cost-effective than phlebotomy when considering the value of returned plasma components, though it is not yet widely available ^[26]B2a.

Step 3: Iron Chelation Therapy, When Phlebotomy Fails or Is Contraindicated

Iron chelation is indicated for patients who cannot tolerate phlebotomy, such as those with severe anemia (hemoglobin persistently <11 g/dL despite iron depletion), poor venous access, or advanced cirrhosis with thrombocytopenia ^[45]A1c. Deferasirox is the preferred oral chelator; deferoxamine (subcutaneous infusion) is an alternative. The Chinese guidelines recommend that chelation be considered only when phlebotomy is not feasible ^[45]A1c. Animal studies have explored novel hepcidin agonists (minihepcidins, thiazolidinones), RNAi therapeutics targeting Tmprss6, and silencing of intestinal DMT1, but these remain investigational and are not approved for clinical use ^{[59]D5[60]D5[20]D5[17]D5}.

Step 4: Lifestyle Modifications

All patients with HH should be advised to abstain from alcohol, as alcohol consumption is a well-established cofactor that accelerates hepatic fibrosis and increases the risk of cirrhosis ^[65]D5[8]D5. Patients should avoid iron supplements, high-dose vitamin C (which can enhance iron absorption and promote oxidative stress), and raw shellfish (which may carry Vibrio vulnificus, a pathogen that thrives in iron-overloaded hosts). A balanced diet low in red meat is reasonable. Regular exercise and weight management are advised to reduce the metabolic syndrome components that can exacerbate steatosis and fibrosis ^[68]D5.

Step 5: Monitoring and Surveillance

Long-term surveillance focuses on detecting complications of iron overload and monitoring the response to therapy. Check serum ferritin and transferrin saturation every 3-6 months during maintenance. Annual liver function tests, fasting glucose, and joint assessment are recommended ^[68]D5. Patients with cirrhosis require semiannual surveillance for hepatocellular carcinoma with ultrasound and alpha-fetoprotein. Liver MRI with iron quantification (R2* or T2* mapping) is a noninvasive tool for monitoring liver iron concentration and is increasingly used to guide therapy ^[53]D5. Bone density assessment should be considered, as iron overload can cause oxidative stress-mediated bone loss ^[58]D5.

Drug / Modality Comparison

What NOT to Do

• Do not use iron chelation as first-line therapy when phlebotomy is feasible; phlebotomy is cheaper, safer, and more effective ^[45]A1c.
• Do not ignore alcohol counseling, abstinence is strongly recommended to reduce fibrosis progression ^[65]D5.
• Do not supplement with vitamin C without careful monitoring of iron status; it can increase free radical production in iron-loaded patients.
• Do not perform phlebotomy in patients with hemoglobin <11 g/dL without first evaluating the cause of anemia ^[68]D5.

Controversies and Guideline Disagreement

No major guideline disagreements were identified for the core management of established HH.

Pearl: Phlebotomy remains the mainstay of therapy; iron depletion to a serum ferritin <50 ng/mL prevents organ damage, and maintenance phlebotomy can be transformed into a regular blood donation program, which recent evidence suggests may also reduce disease risk in asymptomatic C282Y homozygotes ^{[37]B2b[68]D5}.

For patients with hereditary hemochromatosis who require hematopoietic cell transplantation for coexisting bone marrow failure or hematologic malignancy, iron overload fundamentally alters the risk-benefit calculus of conditioning regimens. Although HH itself is not an indication for transplant, the growing recognition of associated aplastic anemia and the toxicity of myelotoxic agents in iron-loaded patients demands a dedicated approach.

Risk of Conditioning-Related Hepatotoxicity

Busulfan, a backbone of myeloablative conditioning, generates oxidative stress that is amplified in the setting of pre-existing iron overload. A case of a 31-year-old man with HFE H63D homozygosity who developed fatal hepatic failure after busulfan-fludarabine conditioning illustrates this synergism ^[69]C4 (4). The liver biopsy showed severe subacute hepatic necrosis, not the sinusoidal obstruction syndrome (SOS) typically expected. Both busulfan and iron overload independently induce oxidative injury, and their combined effect may produce a distinct, more severe hepatocellular injury pattern. Pre-transplant ferritin and transferrin saturation should be measured in all HH patients being evaluated for HSCT; if serum ferritin is >1000 ng/mL, a 6-12 week course of phlebotomy or chelation before conditioning may reduce the risk ^[69]C4 (4). When feasible, alternative conditioning regimens that avoid busulfan (e.g., fludarabine plus melphalan or treosulfan) should be considered, though no comparative data exist for HH-specific populations.

RBC Exchange as a Rapid Iron Depletion Tool

Automated erythrocytapheresis (RBC exchange) can rapidly lower the circulating RBC mass and, consequently, the body iron content. It is a rare indication for hereditary hemochromatosis where the goal is to quickly decrease iron stores, such as before urgent transplant or in patients with severe cardiac iron overload who cannot tolerate repeated phlebotomies ^[70]D5 (5). The procedure uses an apheresis device to remove the patient's erythrocytes and replace them with donor RBCs, accomplishing in one session what would require weeks of phlebotomy. Disadvantages include higher cost, greater donor RBC exposure, and the need for specialist staff. Decision to use RBC exchange should be made in consultation with a transfusion medicine specialist ^[70]D5 (5). No high-quality trials compare RBC exchange with phlebotomy in HH, and the evidence remains at the level of expert opinion.

Transplant in Coexisting Bone Marrow Failure

Aplastic anemia can coexist with HH, as reported in a 5-year-old boy with homozygous HFE c.187C>G mutation who presented with pancytopenia and ecchymoses ^[71]C4 (4). After initial immunosuppressive therapy failed, he underwent haploidentical hematopoietic stem cell transplantation (hHSCT) from his father with a successful outcome. The case highlights two key points: (i) HH should be considered in the workup of idiopathic aplastic anemia, and (ii) HH is not a contraindication to HSCT when the donor is carefully selected. In this instance, the patient's sister was a full HLA match but also had HH, prompting the use of a haploidentical donor. Pre-transplant iron assessment and donor selection that avoids transfusion of iron-loaded grafts are essential ^[71]C4 (4).

Cellular Therapy

No evidence currently supports the use of chimeric antigen receptor T-cell therapy or bispecific antibodies in the management of HH. These modalities remain irrelevant to the pathophysiology of iron overload.

Pearl: In HH patients requiring HSCT, pre-transplant iron assessment (ferritin, TSAT) and avoidance of busulfan-based conditioning may reduce the risk of severe hepatic necrosis, though supporting data are limited to case reports ^[69]C4 (4).

Management of HH centers on phlebotomy-based cytoreduction, with iron chelation as an alternative, while anticoagulation and transfusion support are reserved for specific complications.

Step 1: Phlebotomy as First-Line Cytoreduction

Phlebotomy is the standard of care for all patients with HH and evidence of iron overload (elevated ferritin and transferrin saturation). The 2024 Chinese Society of Hepatology guidelines recommend repeated phlebotomy as the first-line therapy^[45]A1c (1c). A typical regimen removes 500 mL of whole blood (≈200 mg iron) weekly until iron indices normalize, then maintenance every 2-4 months. In a prospective study, a single phlebotomy significantly reduced serum iron, ferritin, and transferrin saturation (all p < 0.0001)^[64]B2b (2b). Long-term phlebotomy prevents progression to cirrhosis and hepatocellular carcinoma; in the Melbourne Collaborative Cohort, iron-overload-related disease developed in 28.4% of male C282Y homozygotes^[16]B2b (2b), and phlebotomy is the established intervention to avert this outcome.

Step 2: Iron Chelation for Phlebotomy-Intolerant Patients

For patients who cannot tolerate phlebotomy (e.g., severe anemia, poor venous access, cardiac disease), iron chelation is an alternative. The Chinese guidelines note that chelation therapy may be used when phlebotomy is not feasible^[45]A1c. Deferasirox or deferoxamine are options; dosing follows standard iron overload protocols. Chelation is less efficient than phlebotomy for reducing body iron and requires serial monitoring of serum ferritin and liver iron concentration by MRI.

Step 3: Anticoagulation for Cardiovascular Complications

Iron overload in HH increases the risk of atrial fibrillation and thromboembolic events. No HH-specific anticoagulation trials exist; management follows standard stroke risk assessment (e.g., CHA₂DS₂-VASc score) with careful evaluation of liver function due to cirrhosis risk. Direct oral anticoagulants are preferred over warfarin in compensated cirrhosis, but avoided in decompensated disease. Portal vein thrombosis in HH-related cirrhosis requires anticoagulation as per general guidelines.

Step 4: Transfusion Support - When to Use

Transfusion is rarely indicated in HH and is generally avoided because it exacerbates iron overload. Transfusion may be necessary for severe anemia (e.g., hemoglobin <7 g/dL) due to aggressive phlebotomy or concurrent causes such as hemolysis . If transfusion is required, concurrent iron chelation should be initiated to prevent additional iron loading. Exchange transfusion has been used in fulminant iron overload with cardiac involvement, although evidence is limited to case reports.

Step 5: Emerging Cytoreductive Therapies

Several novel agents targeting the hepcidin-ferroportin axis are in preclinical development. Minihepcidin PR65 prevented liver iron loading in hepcidin knockout mice^[59]D5 (5). Base editing of the HFE C282Y mutation achieved 67% in vivo correction in murine hepatocytes, reducing hepatic iron overload^[30]D5 (5). Thiazolidinone compounds stimulated hepatic hepcidin and prevented iron overload in hemochromatosis mice^[20]D5 (5). Intestinal DMT1 silencing reduced liver iron in β-thalassemia mice^[17]D5 (5). PKCα inhibition^[76]D5 and RNF217 overexpression^[86]D5 both reduced iron absorption in HH mouse models. Foxo1 activation^[57]D5[73]D5 and endothelial mTORC2-Foxo1 axis modulation^[73]D5 are additional promising targets. These therapies are not yet approved for clinical use.

Controversies and Guideline Disagreement

No major guideline disagreements were identified for this topic. The Chinese guidelines^[45]A1c and Western guidelines (AASLD, EASL) both recommend phlebotomy as first-line therapy. The main area of variability is the ferritin target for stopping phlebotomy: some experts use <50 µg/L, others <100 µg/L. There is consensus that iron chelation is a second-line option.

Pearl: Phlebotomy remains the cornerstone of HH management, with iron chelation reserved for those intolerant to phlebotomy; anticoagulation for atrial fibrillation follows standard risk scores with liver function monitoring, and transfusion is generally avoided to prevent further iron loading.

The therapeutic timeline for hereditary hemochromatosis (HH) spans from crude venesection to evidence-based phlebotomy protocols, guided by landmark epidemiological studies and mechanistic trials. The 1996 identification of the HFE gene catalyzed a shift from clinical diagnosis to molecular screening, but the optimal treatment strategy emerged only after large population-based studies clarified penetrance and risk.

Early Epidemiological Landmarks

Two landmark studies from Australia defined the natural history of HFE-related HH. The Busselton population-based study (1999) found that only 8 of 16 C282Y homozygotes had clinical features of hemochromatosis, and one quarter had persistently normal serum ferritin over four years ^[92]B2c. This established that the mutation has incomplete penetrance. The Melbourne Collaborative Cohort Study (2008) followed 31,192 adults for 12 years and reported that iron-overload-related disease developed in 28.4% of male C282Y homozygotes but only 1.2% of female homozygotes ^[16]B2b. Male homozygotes with serum ferritin ≥1000 µg/L were more likely to have fatigue, arthritis, and liver disease. These data provided the rationale for targeting ferritin <1000 ng/mL as a treatment threshold to prevent cirrhosis and hepatocellular carcinoma ^[89]A1c.

The Phlebotomy Standard

Phlebotomy has been the mainstay of therapy for over a century, but its modern protocol was refined by these epidemiological insights. The ACG Clinical Guideline recommends reducing serum ferritin to 50-100 ng/mL via weekly phlebotomy of 500 mL, then maintaining it below 100 ng/mL ^[89]A1c. Liver biopsy was historically required to stage fibrosis, but noninvasive MRI with R2* relaxometry now quantifies hepatic iron accurately and has largely replaced biopsy ^[100]D5. The threshold of serum ferritin <1000 ng/mL at diagnosis remains the strongest predictor of a low risk of advanced fibrosis, guiding the need for urgent phlebotomy ^[89]A1c.

Adjunctive Therapies

Several adjunctive strategies have been tested to reduce phlebotomy burden. The first randomized controlled trial of a proton pump inhibitor (PPI) in HH demonstrated that pantoprazole 40 mg/day significantly reduced the need for phlebotomy in C282Y homozygotes over 12 months ^[96]A1b. This effect is thought to be due to reduced dietary iron absorption by increasing gastric pH. Dietary polyphenol supplements have also been investigated. A natural polyphenol supplement (black tea, cocoa, grape juice) reduced fractional iron absorption by ~40% in a single-blind crossover trial (n=14) ^[93]A1b. Similarly, Ilex paraguariensis leaf infusion decreased postprandial serum iron area under the curve significantly (P < 0.001) ^[94]A1b. However, procyanidin supplementation (100 mg) did not affect iron absorption in HH in a double-blind trial ^[95]A1b, indicating that not all polyphenols are effective. These adjuncts are not yet standard of care but may be considered for motivated patients.

Novel Horizons and Abandoned Approaches

Iron chelation (deferasirox, deferoxamine) is reserved for patients who cannot tolerate phlebotomy due to anemia or severe comorbidities ^{[45]A1c[89]A1c}. The historical use of deferoxamine as first-line therapy has been abandoned because phlebotomy is more effective, safer, and cheaper. In the research arena, targeting the hepcidin-ferroportin axis is promising. In a murine model of hemochromatosis (Hjv-/- mice), overexpression of the E3 ubiquitin ligase RNF217 in intestinal enterocytes reduced iron accumulation in serum and organs by directly degrading ferroportin, bypassing hepcidin regulation ^[86]D5. This highlights a potential therapeutic strategy that could one day reduce phlebotomy frequency. The pursuit of such targeted therapies reflects the evolution from a one-size-fits-all venesection approach to personalized modulation of iron absorption.

Pearl: The serum ferritin threshold of 1000 ng/mL at diagnosis remains the most clinically useful predictor of advanced fibrosis, and phlebotomy to maintain ferritin below 100 ng/mL prevents progression to cirrhosis ^{[16]B2b[89]A1c}.

Despite effective iron depletion, patients with hereditary hemochromatosis (HH) remain at risk for several complications arising from cumulative iron toxicity, host immune alterations, and associated comorbidities. The following table catalogues the major complications, their approximate frequency, prevention strategies, and management approaches.

Infection Risk

Infection risk is paradoxically increased in HH despite some evidence of protected neutrophil function ^[80]C4. In a large Danish cohort, C282Y homozygotes had a 40% higher risk of any infection, 69% higher risk of sepsis, and 2.34-fold higher risk of death from infection compared with noncarriers ^[55]B2b. Importantly, this risk persisted even in individuals with normal plasma iron, transferrin saturation, or ferritin, and in those without liver disease, diabetes, or heart failure ^[55]B2b. The mechanism may involve altered iron handling in macrophages and neutrophils, leading to impaired bactericidal capacity against certain pathogens such as Yersinia species ^[29]D5[81]D5. Mouse models suggest that Hfe deficiency in macrophages can paradoxically protect against Salmonella by inducing lipocalin-2, but this protection is lost with high serum iron ^{[101]D5[81]D5}.

Hepatic Complications

Cirrhosis risk is strongly linked to the degree of iron loading; threshold hepatic iron concentrations have been identified from population studies ^[8]D5. Alcohol consumption, steatosis, and coexistent viral hepatitis are important cofactors ^[8]D5. HCC can occur even in the absence of cirrhosis, but the BCLC staging system accurately stratifies survival, and HH patients achieve comparable outcomes to other liver diseases after curative therapy ^[36]B2b.

Bone and Endocrine Health

Osteoporosis is a frequent complication, particularly when cirrhosis or hypogonadism coexists ^[102]D5. The underlying mechanisms are unclear but likely involve both direct iron toxicity and secondary metabolic effects ^[102]D5. Hypogonadotropic hypogonadism due to iron deposition in the pituitary and testes can impair spermatogenesis and testosterone production, contributing to bone loss and infertility ^[66]D5.

Pearl: C282Y homozygotes remain at increased infection risk (HR 1.40 for any infection) even with normal ferritin, suggesting that factors beyond iron overload contribute to immune dysfunction ^[55]B2b.

The complications of cirrhosis, hepatocellular carcinoma, and extrahepatic organ damage define the clinical trajectory of untreated hereditary hemochromatosis. Yet the disease is highly variable, with outcomes determined by the interplay of genotype, iron burden, and environmental cofactors.

Natural History and Progression

Untreated HFE p.C282Y homozygotes accumulate iron slowly over decades; only a minority progress to cirrhosis. The risk of hepatic fibrosis and cirrhosis is directly proportional to the degree of iron loading, with threshold hepatic iron concentrations identified from population studies ^[8]D5. Crucially, cofactors accelerate this progression. Excess alcohol consumption is one of the most potent modifiers, with steatosis and coexistent viral hepatitis also implicated ^[8]D5. Genetic polymorphisms in fibrogenesis, antioxidant, and inflammatory genes may further modulate risk, though none alone is a major determinant ^[8]D5[21]C4. In HFE disease, arthritis and arthropathy are common, even in the absence of cirrhosis, and may be driven by factors beyond iron overload ^[42]C4.

Impact of Genotype on Prognosis

Non-HFE forms of HH follow a distinctly more aggressive course. HJV and HAMP mutations cause juvenile-onset disease (often before age 30) with severe iron overload, cardiomyopathy, and hypogonadism ^[42]C4. TFR2 mutations present later in adolescence or early adulthood with intermediate severity ^[42]C4. Among HJV homozygotes, mutations in exons 2-3 confer a 91.3% risk of early-onset HH compared with 66.0% for exon 4 mutations; hypogonadism is more frequent with missense (72.6%) than nonsense mutations (35.7%) ^[33]C4.

Data from ^[42]C4[33]C4.

Prognosis After Treatment of Complications

Once HCC develops, outcomes depend on stage at diagnosis and treatment modality. In a matched cohort study of HH patients with HCC, 5-year survival after curative therapy was 77% (80% for liver transplantation , 67% for resection or radiofrequency ablation ) versus 15% for noncurative therapy (23% for transarterial chemoembolization ) ^[36]B2b. Survival was comparable to non-HH HCC controls (; p=0.839), and BCLC stage independently predicted survival ^[36]B2b. These data underscore that timely, stage-appropriate therapy yields outcomes equivalent to other liver disease etiologies.

Infection Risk and Other Comorbidities

HFE deficiency may paradoxically protect against certain intracellular pathogens (e.g., Salmonella) via enhanced lipocalin-2-mediated iron withdrawal ^[101]D5, but increase susceptibility to others such as Yersinia ^[29]D5. A meta-analysis found a trend toward increased breast cancer risk in C282Y homozygotes (OR 1.36, 95%), though this does not yet justify changes in surveillance ^[34]B2a.

Pearl: The BCLC staging system accurately stratifies survival in HH-associated HCC, with 5-year survival of 77% after curative therapy, comparable to other liver disease etiologies ^[36]B2b.

The natural history of hereditary hemochromatosis is modified by age, sex, and physiological states such as pregnancy and menopause , requiring tailored management across the lifespan.

Pregnancy

Pregnancy imposes increased iron demands, but this does not meaningfully reduce body iron stores in HFE p.C282Y homozygotes. In Hfe-/- mouse models, multiple pregnancies failed to lower hepatic iron concentration; total iron per organ was actually higher in pluriparous females ^[109]D5. Phlebotomy is generally deferred during pregnancy unless severe iron overload with organ dysfunction is present, as the physiological anemia of pregnancy and potential for hypotension make routine venesection unsafe. Iron supplementation should be avoided unless documented iron deficiency anemia, because high-dose oral iron may exacerbate copper depletion, a concern in iron-loading disorders ^[108]D5. Postpartum, serum ferritin should be reassessed; the expected rise after menopause is particularly steep in p.C282Y homozygotes, with ferritin increasing by a factor of 3.6 (95% CI 1.8-7.0) in the first 10 years after menopause ^[104]B2b.

Pediatrics

Genetic testing for HFE mutations in asymptomatic minors remains controversial. Professional guidelines generally recommend deferring predictive testing for adult-onset conditions such as hereditary hemochromatosis until the child can provide informed consent, unless clinical suspicion of iron overload exists ^[105]D5. When hyperferritinemia is identified in a child, the differential must include hereditary hyperferritinemia-cataract syndrome (HHCS), an autosomal dominant FTL mutation causing bilateral pediatric cataract and ferritin levels of 971-4899 ng/mL without iron overload ^[40]C4. Concurrent HFE mutations (e.g., p.H63D) may further elevate ferritin, but do not alter the benign prognosis of HHCS ^[40]C4. In the rare child with confirmed iron overload, phlebotomy can be initiated at adult-equivalent volumes adjusted for weight, but targets (ferritin <50 μg/L) remain the same.

Elderly

Elderly patients with hereditary hemochromatosis have accelerated arthropathy: in a nationwide analysis, 6.3% of HH patients underwent joint replacement arthroplasty, with elderly patients and young-adult females at highest odds compared with age- and sex-matched controls ^[110]B2b. Mean age at arthroplasty was 66 years ^[110]B2b. Clinicians should maintain a low threshold for orthopedic referral in older HH patients with joint pain, as iron-mediated arthropathy progresses faster than osteoarthritis. Postmenopausal women require particular attention: serum ferritin rises sharply after menopause, and projected levels may exceed 200 μg/L even without clinical disease ^[104]B2b. Phlebotomy targets in the elderly should account for reduced cardiovascular reserve and common comorbidities (e.g., chronic kidney disease, heart failure); a slower induction schedule (e.g., 250-300 mL per session) may be better tolerated. Surveillance for hepatocellular carcinoma and cirrhosis, as outlined in Section 14, remains essential regardless of age.

Pearl: In elderly women with HH, the postmenopausal ferritin surge (3.6-fold in 10 years) and increased risk of joint replacement (6.3% vs 3.4%) mandate proactive phlebotomy and early orthopedic evaluation, do not attribute joint pain solely to age-related osteoarthritis.

Beyond the nuanced management of iron burden during pregnancy, the lifelong goal for every patient with hereditary hemochromatosis, and their at-risk relatives, is prevention of iron accumulation and its complications through systematic screening, early detection, and sustained surveillance.

Screening Strategies

Cascade genetic testing of first-degree relatives is mandatory once a proband is identified; siblings and offspring have a 50% chance of carrying the pathogenic mutation in autosomal dominant Ferroportin disease or, for recessive HFE disease, a 25% risk of homozygosity ^[18]D5. The EMQN best practice guidelines recommend HFE genotyping (p.C282Y and p.H63D) as the first-line test for suspected HH, recognizing that homozygosity for p.C282Y is not sufficient to diagnose disease but is a prerequisite for early intervention ^[111]A1c. Economic analyses consistently show that both phenotype (transferrin saturation, serum ferritin) and genotype screening are cost-effective compared with no screening, with a favorable incremental cost-effectiveness ratio across multiple health systems ^[26]B2a.

Novel risk modifiers now allow individual-level risk stratification. In a FinnGen cohort of 420,543 individuals, donating blood at least twice a year reduced the risk of clinical hemochromatosis in male C282Y homozygotes from 0.16 to 0.018 (80%), equivalent to the risk of a C282Y-H63D compound heterozygote ^[37]B2b. The S65C variant protects against severe disease (incidence ratio 0.328, 95%) ^[37]B2b. These data support a strategy of targeted, risk-adapted screening rather than universal population screening, particularly in populations of Northern European descent.

Surveillance and Secondary Prevention

Once iron overload is established, the goal of surveillance is to prevent progression to cirrhosis, hepatocellular carcinoma , and cardiac complications. Abdominal MRI with T2* or T2 spin-echo sequences is the key non-invasive tool: a negative likelihood ratio of 0.05-0.10 makes it highly accurate for ruling out liver iron overload, though positive likelihood ratios (4.86-8.85) are insufficient to definitively diagnose overload in the absence of biopsy ^[103]A1a. The ACG guideline recommends screening for HH as part of the evaluation of any unexplained elevation of ALT or AST (true normal ALT 29-33 IU/L for men, 19-25 IU/L for women) ^[91]A1c.

For women with HFE variants, especially C282Y homozygotes, a meta-analysis of 73,981 participants found a trend toward increased breast cancer risk (OR 1.36, 95%) but with substantial heterogeneity; current evidence does not yet justify changes in routine surveillance, though prospective studies are warranted ^[34]B2a.

Patient Education and Lifestyle

Dietary counseling remains central: Ilex paraguariensis (yerba mate) leaf infusion significantly inhibits non-heme iron absorption (AUC 173.3 vs. 1449.4 μmol·h⁻¹·L⁻¹, p<0.001) and can be offered as a safe, inexpensive adjuvant ^[94]A1b. Preclinical evidence suggests that minihepcidin agonists (e.g., PR65) may prevent iron loading in hepcidin-deficient states, but human data are lacking ^[59]D5. Patients should be advised to avoid medicinal iron and vitamin C supplements with meals, and to maintain regular phlebotomy compliance.

Pearl: The single most impactful preventive action for an asymptomatic C282Y homozygote is regular blood donation twice a year; this reduces the risk of developing clinical hemochromatosis to that of a compound heterozygote ^[37]B2b.